• HPR209 Criteria for Decision-Making on Drug Financing in Spain: How Do We Measure Them and What Relevance Does Each One Have?

    Dec 1, 2023, 00:00

  • P50 Joint Modelling of Intermediate Longitudinal Biomarkers to Predict Overall Survival in Patients with Solid Tumors

    Dec 1, 2023, 00:00

  • HPR131 What Is a Year of Life Worth? Empirical Findings from Worldwide Economic Studies on the Value of a Statistical Life

    Dec 1, 2023, 00:00

  • EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

    Dec 1, 2023, 00:00

  • EE759 Willingness-To-Pay for a QALY: A New Approach to Estimate Cost-Effectiveness Threshold Applied to France

    Dec 1, 2023, 00:00

  • EE238 Cost-Effectiveness of Online Cognitive Behavioral Therapy for Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Compared to Online Activity Management: FITNET-NHS Trial Findings

    Dec 1, 2023, 00:00

  • HPR38 Arbitral Awards on Reimbursement Prices Since 2019 in Germany: What We Can Learn?

    Dec 1, 2023, 00:00

  • EE91 A Systematic Literature Review of Health-Related Quality of Life, Costs, and Healthcare Resource Use in Primary Biliary Cholangitis

    Dec 1, 2023, 00:00

  • HSD116 Actual Use in Real World Setting of Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma in EU5 Countries and in the US

    Dec 1, 2023, 00:00

  • PT5 The Role of EUnetHTA 21 in Promoting Patient Engagement

    Dec 1, 2023, 00:00

  • EE611 Economic Evaluation of Person-Centred Care Using a Digital Platform and Structure Telephone Support for People with Chronic Heart Failure and/or Chronic Obstructive Pulmonary Disease

    Dec 1, 2023, 00:00

  • EPH239 Incremental Cost Burden of Major Depressive Disorder in Patients with Rheumatoid Arthritis in Korea

    Dec 1, 2023, 00:00

  • EE506 RNA Interference Therapies for hATTR Amyloidosis With Polyneuropathy: Differential Healthcare Resource Use and Direct and Indirect Cost Consequences Associated With Vutrisiran Versus Patisiran

    Dec 1, 2023, 00:00

  • Disclosure Information

    Dec 1, 2023, 00:00

  • EE289 Comparison of the Clinical and Economic Impact of Two COVID-19 mRNA Vaccines in High Risk Individuals in the Tokyo Prefecture

    Dec 1, 2023, 00:00

  • EE112 Economic Burden of SLE in Nordic Countries - a Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EPH128 Evaluation of the Effects of the COVID-19 Pandemic on Depression Among the Under 20-Year-Old Population in Japan, the US, and Germany Before and During the COVID-19 Pandemic: A Retrospective Observational Study Using Real-World Data

    Dec 1, 2023, 00:00

  • HTA358 Value-Based Contracts Types Across Global Healthcare Systems: Comparing Perceptions Between Finance-Based and Outcomes-Based Agreements

    Dec 1, 2023, 00:00

  • RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study

    Dec 1, 2023, 00:00

  • HTA229 PICO Criteria Applied in Joint Action 3 Differ From National HTA Requirements: A Review of Oncology Drug Assessments in Denmark, France, Germany, and Sweden

    Dec 1, 2023, 00:00

  • RWD78 Hospitalization Costs for Patients with Acute Appendicitis: An Update Using Real-World Data from a Large Province in China

    Dec 1, 2023, 00:00

  • HSD64 Breast Cancer in the COVID-19 Pandemic Era: An Old Tool with Modern Innovations

    Dec 1, 2023, 00:00

  • HTA355 A Roadmap Towards Implementing HTA in Oman

    Dec 1, 2023, 00:00

  • PCR5 First Interim Analysis of Patient-Reported Outcomes in View Study: A Multicenter, Single-Arm, Prospective, Non-Interventional Study of Vonoprazan in Real-World Clinical Practice in China

    Dec 1, 2023, 00:00

  • HTA331 Health Technology Assessment of Point-of-Care Diagnostics for Antimicrobial Resistance; Perspectives and Recommendations from an Expert Advisory Panel

    Dec 1, 2023, 00:00

  • HTA223 Comparative Evaluation of the HTA Evidence Requirements and Outcomes for Digital Health Technologies in Germany and UK

    Dec 1, 2023, 00:00

  • EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin

    Dec 1, 2023, 00:00

  • MT76 DiMe Library of Digital Endpoints: Strengths, Weaknesses, and Pathways for Improvement in Digital Health Research

    Dec 1, 2023, 00:00

  • MT46 Implementation of Cost-Consequences Analysis As an Economic Evaluation Method for Artificial Intelligent (AI) Medical and Digital Technologies. the Case of Hosmartai (HORIZON 2020 FUNDED)

    Dec 1, 2023, 00:00

  • PCR177 Assessing the Impact of Relapses on Patient Outcomes in NMOSD

    Dec 1, 2023, 00:00

  • HSD92 Factors Having an Impact on the Prescription of Cancer Treatments in Hospital at Home Program in Bronchopulmonary Cancer: A French Claims Database Analysis (2016-2021)

    Dec 1, 2023, 00:00

  • EPH115 Primary Prevention Strategies for Stroke: A Multilevel Approach

    Dec 1, 2023, 00:00

  • RWD113 Switching to TNFi Versus Non-TNFi Biologics in Ulcerative Colitis Patients: Real-World Outcomes from a German Claims Data Analysis

    Dec 1, 2023, 00:00

  • EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • PCR240 Incorporating a Holistic Patient Perspective When Assessing the Value of Non-Small Cell Lung Cancer (NSCLC) Therapies

    Dec 1, 2023, 00:00

  • CO128 Health-Related Quality of Life in Generalized Myasthenia Gravis- the Relationship between MG-ADL and EQ-5D-5L in the Raise Study

    Dec 1, 2023, 00:00

  • OP12 Adherence to Intravenous to Oral Switching Criteria in a Tertiary Governmental Hospital in Riyadh, Saudi Arabia

    Dec 1, 2023, 00:00

  • EE194 Economic Evaluation of Tofacitinib for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis in Greece

    Dec 1, 2023, 00:00

  • EE489 Healthcare Utilization and Costs Among Treatment-Experienced Medicaid Beneficiaries Utilizing Single-Treatment Versus Multi-Treatment Regimens for HIV

    Dec 1, 2023, 00:00

  • EE152 The Implicit Devaluation of Health Benefits Over Time in NICE Decision-Making Criteria: Assessing NICE’s Static Willingness to Pay Threshold in the Context of Inflation.

    Dec 1, 2023, 00:00

  • EE286 Cost Effectiveness and Public Health Impact of Implementing Gender-Neutral Vaccination with the 9-Valent Human Papillomavirus Vaccine in Turkiye

    Dec 1, 2023, 00:00

  • MSR125 How Prognostic Factors Are Identified for Population Matching Analysis

    Dec 1, 2023, 00:00

  • MT59 Overview of Approved Digital Therapeutics in Belgium

    Dec 1, 2023, 00:00

  • PT45 Disease Relapse and Adverse Events During the Combination Use of Clozapine and Long-Acting Injectable Antipsychotics and During the Clozapine Monotherapy

    Dec 1, 2023, 00:00

  • PCR20 Preferences for Cancer Treatments: A Discrete-Choice Experiment with Adult Patients with Cancer in Europe

    Dec 1, 2023, 00:00

  • HPR132 The Role of Economic Evaluation in HTA in Spain

    Dec 1, 2023, 00:00

  • EPH119 Disease Burden and Cost-of-Illness of Hepatocellular Carcinoma in Portugal: A Model-Based Analysis Considering the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm System

    Dec 1, 2023, 00:00

  • SA37 A Real-World Evaluation of People with Drug-Resistant Focal Epilepsy Across Six European Countries

    Dec 1, 2023, 00:00

  • MSR115 Using Machine Learning to Assess Potential Cases of Transthyretin Cardiac Amyloidosis in Brazil: A Retrospective Database Approach

    Dec 1, 2023, 00:00

  • CO27 The Feasibility of Systematic Goal Quality Assurance During Goal Attainment Scaling in a Rare Disease

    Dec 1, 2023, 00:00

  • HTA356 Bridging the Gap between National and EUNETHTA21 HTA Methods. Are Marketing Authorisation Holders Ready for Joint Clinical Assessments?

    Dec 1, 2023, 00:00

  • EE455 Cost Saving Potential of Rapid Microbiological Methods: Case Form Bulgaria

    Dec 1, 2023, 00:00

  • EE3 Micro-Costing Analysis for the Treatment of Atrial Fibrillation: An Economic Evaluation

    Dec 1, 2023, 00:00

  • HPR123 Risk Sharing Agreements in the Asia-Pacific Region: A Systematic Literature Review on New Pricing Modalities to Improve Value Access

    Dec 1, 2023, 00:00

  • SA13 Can Models for Surrogate Endpoint Evaluation Be Used to Predict Generic Measures From Disease Specific Measures of Health Related Quality of Life Based on Summary Data?

    Dec 1, 2023, 00:00

  • MSR135 Do You Really Need to See the Doctor? Developing a Machine Learning Approach for Optimal Assignment Rules of Physician Visits for Patients After Knee Replacement

    Dec 1, 2023, 00:00

  • EE30 Framework Concepts for Economic Evaluation of New Antibiotics

    Dec 1, 2023, 00:00

  • EE627 The Potential Value of Identifying Type 2 Diabetes Subgroups in the CPRD Cohort for Guiding Intensive Treatment: A HTx Study Comparing Novel Data-Driven Clustering to Traditional Risk-Driven Subgroups

    Dec 1, 2023, 00:00

  • SA10 The Burden of Illness of Vasomotor Symptoms Associated with Menopause

    Dec 1, 2023, 00:00

  • HTA124 Can You Have a Common Approach to the Statistical Analysis Plan When Conducting Real-World Evidence Studies to Meet Multi-HTA Requirements?

    Dec 1, 2023, 00:00

  • EE617 A Systematic Review of Economic Evaluations of Balloons and Stents for Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

    Dec 1, 2023, 00:00

  • PCR133 Patient Experience of Second-Line Treatment for Relapsed/Refractory Chronic Lymphocytic Leukaemia in UK Clinical Practi Study Methodology

    Dec 1, 2023, 00:00

  • EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective

    Dec 1, 2023, 00:00

  • EE567 Economic Evaluations of Pharmacological Interventions for Lupus Population – a Targeted Literature Review

    Dec 1, 2023, 00:00

  • PCR215 Usability Testing of a Non-Consumer Smartphone Device for ePRO Data Collection

    Dec 1, 2023, 00:00

  • HSD55 Sex Differences in Guideline Adherence for Coronary Angiography in Patients with Suspected Chronic Coronary Artery Disease in Germany: Insights from the ENLIGHT-KHK Trial

    Dec 1, 2023, 00:00

  • PCR62 Treatment Satisfaction and Health-Related Quality of Life in People Living With HIV Receiving DTG/3TC Who Are Treatment Experienced or Treatment Naive in Europe

    Dec 1, 2023, 00:00

  • HPR106 New Proposed European Commission Pharmaceutical Regulation – Potential Changes and Impact on Manufacturers With a Focus on Eastern Southern European Member States

    Dec 1, 2023, 00:00

  • HSD4 Institutional and Geographical Variation in Discharge Destination Among Admission Avoidance Municipal Inpatient Acute Care Units in Norway

    Dec 1, 2023, 00:00

  • SA60 Key Challenges in Gene Therapy Development for Usher Syndrome: Insights from Machine-Assisted Rapid Scoping Review

    Dec 1, 2023, 00:00

  • EPH178 Burden of the Disease and Management in COVID-19 Hospitalized Patients in MSO and Home Care in Fran COVID-Hosp Study (2020-2022)

    Dec 1, 2023, 00:00

  • MT63 Value Assessment of Combination Digital Health Technologies Under New NICE Evidence Standards Framework: Evidence Submitted and Key Factors for Positive Recommendation

    Dec 1, 2023, 00:00

  • EE52 Evaluation of the Economic Impact of Initial Diagnostic Modality Selection for Patients Suspected of Having Colorectal Cancer Liver Metastases or Hepatocellular Carcinoma in the UK

    Dec 1, 2023, 00:00

  • Challenges in Modeling Oncology Outcomes

    Dec 1, 2023, 00:00

  • RWD65 Patterns of Antibiotic Prescribing in a Tertiary Hospital Using Real-World Data

    Dec 1, 2023, 00:00

  • EE120 Cost-Effectiveness of Difelikefalin for the Treatment of Moderate to Severe Chronic Kidney Disease-Associated Pruritus (CKD-AP) in Adult Patients Receiving in-Centre Haemodialysis

    Dec 1, 2023, 00:00

  • SA72 Current Practices for the Selection of Effect Modifiers and Confounders in Population-Adjusted Indirect Comparisons (PAIC): A Review of Technology Appraisals (TA)

    Dec 1, 2023, 00:00

  • HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?

    Dec 1, 2023, 00:00

  • RWD59 Economic and Healthcare Resource Utilization by Transthyretin Amyloid Cardiomyopathy Patients in Spain: Observations From the PRACTICA Study

    Dec 1, 2023, 00:00

  • MSR2 Development of an Algorithm to Identify the Type of Diabetes in the French Administrative Health Care Database “Système National Des Données De Santé” (SNDS)

    Dec 1, 2023, 00:00

  • SA42 Project SATURN – A Real-World Evidence and Data Collaboration With Existing European Datasets in Osteogenesis Imperfecta to Support Future Therapies

    Dec 1, 2023, 00:00

  • EE83 Cost-Utility and Budget Impact Analyses of Cervical Cancer Screening Using Self-Collected Sample Kit for HPV DNA Testing in Thailand

    Dec 1, 2023, 00:00

  • HPR36 Volume Vs Value: Understanding the Pricing Dynamics of Multi-Indication Therapies in Weighted-Average List Price Markets

    Dec 1, 2023, 00:00

  • HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?

    Dec 1, 2023, 00:00

  • OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)

    Dec 1, 2023, 00:00

  • EE502 Budget Impact Analysis of Transanal Irrigation for the Treatment of Low Anterior Resection Syndrome in Spain

    Dec 1, 2023, 00:00

  • RWD18 Characterization of Time-to-Treatment-Discontinuation (TTTD) as a Proxy for Progression-Free Survival (PFS) in Real-World Evidence (RWE) Based Analyses of Relapsed-Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • PCR228 Among European Individuals with Major Depressive Disorder, Higher Severity of Insomnia Symptoms Is Independently Associated with Poorer Health-Related Outcomes

    Dec 1, 2023, 00:00

  • SA68 Consistency Between Network Meta-Analysis and Real-Word Data Analysis: Comparison of Changes in Hemoglobin A1c Levels After Treatment with Metformin Vs the Other Oral Antidiabetics in Japanese Patients with Type 2 Diabetes

    Dec 1, 2023, 00:00

  • SA2 A Meta-Regression Tool: Assessing the Relationship Between Risk Factors and Events Development

    Dec 1, 2023, 00:00

  • HTA131 Cost-Effectiveness Threshold in Denmark's New Health Technology Assessment Process: What Do We Know so Far?

    Dec 1, 2023, 00:00

  • EE23 Cost Utility Analysis of Once-Weekly Semaglutide and Dulaglutide for Patients With Type 2 Diabetes in Saudi Arabia

    Dec 1, 2023, 00:00

  • HTA256 Identifying Current ATMP Market Access Challenges and Strategies in France, Germany, Italy, and Spain

    Dec 1, 2023, 00:00

  • HTA258 A Hospital-Based Health Technology Assessment of Near-Infrared Fluorescence Using Indocyanine Green for Sentinel Lymph Node Mapping for Breast Cancer and Gynecologic Cancer

    Dec 1, 2023, 00:00

  • EPH159 Evaluation of Invasive Pneumococcal Disease and Pneumococcal Vaccination Coverage in a Hospital of Spain

    Dec 1, 2023, 00:00

  • EE527 The Indirect Costs and Burden of Vaccine Preventable Cancers Mortality in Middle East and North Africa (MENA) Countries

    Dec 1, 2023, 00:00

  • EE676 Cost Considerations: Exploring the Economic Implications of Choosing SC or IV Administration

    Dec 1, 2023, 00:00

  • CO57 A New Approach in Network Meta-Analysis Using Blended Survival Curves to Extrapolate Long-Term Survival from Immature Data

    Dec 1, 2023, 00:00

  • HTA224 Improving Access to Behavioral and Mental Health Therapies in the EU: An Analogue Assessment Deep Dive

    Dec 1, 2023, 00:00

  • RWD131 A Nationwide Feasibility Study and Study Concept to Assess the Burden of Duchenne Muscular Dystrophy (DMD) in Finland

    Dec 1, 2023, 00:00

  • EPH243 Overview of Lung Cancer Screening Studies in France and Bordering Countries

    Dec 1, 2023, 00:00

  • HTA275 Trends in Medical Services Reimbursement Outcomes in Australia: A Novel and Comprehensive Analysis

    Dec 1, 2023, 00:00

  • HPR135 The Need for Novel Mechanisms to Tackle the Global Antimicrobial Resistance (AMR) Threat: Are Innovative Payment Models Enough?

    Dec 1, 2023, 00:00

  • EE374 Estimating the Impact of Tumors of the Oesophageal and Gastro-Oesophageal Junction on Work, Leisure and Household Activity Times: Evidence from a Patient Survey in Switzerland

    Dec 1, 2023, 00:00

  • EE696 Economic and Clinical Burden Associated with Respiratory Syncytial Virus (RSV) and Expected Impact of Universal Immunization with Nirsevimab Among All Infants in Their First Rsv Season Against Standard of Care in Italy

    Dec 1, 2023, 00:00

  • EE38 Cost-Effectiveness Analysis of the NEON Intervention for People With Psychosis and Non-Psychosis Mental Health Problems

    Dec 1, 2023, 00:00

  • EE480 Cost-Effectiveness Analysis of an Implantable Device for Chronic Gastro-Oesophageal Reflux Disease in Sweden

    Dec 1, 2023, 00:00

  • MSR150 Artificial Intelligence (AI) in Performing Landscape Review and Linguistic Analysis for Curative Intent in Prostate Cancer (PC)

    Dec 1, 2023, 00:00

  • HSD35 Treatment and Dosage Patterns of Oral Corticosteroids Among Patients With Myasthenia Gravis: A Tale of Two Countries

    Dec 1, 2023, 00:00

  • EE654 Occupational Impact of Tardive Dyskinesia: A Cross-Sectional, International Survey Assessing the Perceptions and Experiences of Patients With TD and Physicians Who Treat TD

    Dec 1, 2023, 00:00

  • P27 How Untruthfulness in Self-Reported Medication Adherence Influences Treatment Preferences: A Discrete Choice Experiment

    Dec 1, 2023, 00:00

  • EE357 Cost per Responder Analysis Comparing Adagrasib and Sotorasib in Patients With KRAS G12C-Mutated Previously Treated Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EE248 Evolution in Price Levels of Orphan Medicinal Products (OMP): Looking Back at the Past Decade

    Dec 1, 2023, 00:00

  • HPR198 By Any Genes Necessary: Review of Pipeline Developments and Access Hurdles Likely to be Faced By Gene Therapies

    Dec 1, 2023, 00:00

  • EPH225 The Shifting Patterns of Childhood Obesity: Insights from Population-Based Data

    Dec 1, 2023, 00:00

  • HPR104 A Review of Biosimilar Utilization across EU4 and UK Since the Introduction of the First Biosimilar

    Dec 1, 2023, 00:00

  • HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review

    Dec 1, 2023, 00:00

  • PCR166 Regaining Activities of Daily Living After Stroke – What Matters Most for Patients in Neurorehabilitation?

    Dec 1, 2023, 00:00

  • HTA8 Health Technology Assessment (HTA) Case Studies: Comparing Acceptability of Real-World Evidence (RWE) in Appraisals for Oncology Medicines

    Dec 1, 2023, 00:00

  • PCR171 Translation and Cross-Cultural Validation of the Chinese Version of Adult Social Care Outcomes Toolkit for Service Users in Hong Kong

    Dec 1, 2023, 00:00

  • HPR139 Access to Targeted Therapies for Solid Tumors in Turkey

    Dec 1, 2023, 00:00

  • EE141 Budget Impact Model for the Swiss Healthcare System: Assessing Potential Budget Savings of an Adapted Fall-2023-COVID-19 Vaccination Strategy

    Dec 1, 2023, 00:00

  • EPH79 Epidemiology of Systemic Mastocytosis (SM) and Indolent Systemic Mastocytosis (ISM) in Germany

    Dec 1, 2023, 00:00

  • SA51 Definition and Methodology of Rapid Literature Reviews

    Dec 1, 2023, 00:00

  • HPR162 Pharmaceutical Rebates – An Anglo-French Comparison

    Dec 1, 2023, 00:00

  • HSD33 Horizontal Inequities in the Healthcare Expenditures for Communicable Disease: An Evidence from the National Sample Survey Data

    Dec 1, 2023, 00:00

  • CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib

    Dec 1, 2023, 00:00

  • RWD25 Healthcare Resource Utilization and Costs in Patients Experiencing Severe Cardiac Events Following a COPD Exacerbation: Results from EXACOS-CV Studies in Spain, Germany, the Netherlands and Canada

    Dec 1, 2023, 00:00

  • HPR82 The Comparative Analysis of Accelerated Coverage Pathways for Innovation (ACPI) for Digital Technologies: In the Landscape of Germany, France, and the United Kingdom

    Dec 1, 2023, 00:00

  • MT74 The Impact of Installing a Rfid Cabinet for the Inventory of Intraocular Lenses As Part of the Cataract Surgery Pathway: A Spanish Public Hospital Perspective

    Dec 1, 2023, 00:00

  • EE568 Does the Introduction of an Infliximab Biosimilar Always Result in Savings for Hospitals? A Descriptive Study Using Real-World Data

    Dec 1, 2023, 00:00

  • EE115 Cost-Effectiveness Analysis of Using Ketoanalogues of Essential Aminoacids in Patients With Chronic Kidney Disease in Kazakhstan

    Dec 1, 2023, 00:00

  • MSR153 Can ChatGPT Generate Synthetic Data to Train Systematic Literature Review Machine Learning Models?

    Dec 1, 2023, 00:00

  • RWD62 Dupixam: An SNDS (SYSTÈME NATIONAL DES DONNÉES DE SANTÉ) Study to Characterize Patients Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis in France

    Dec 1, 2023, 00:00

  • HPR124 Opportunities for Improving Healthcare for Migrant Populations, as Identified by Healthcare Teams in Various Regions of Chile

    Dec 1, 2023, 00:00

  • HPR153 Market Access Strategies for Advanced Therapy Drugs: A Comparative Analysis of the European and American Markets, Authorizations and Withdrawals

    Dec 1, 2023, 00:00

  • EE742 The Comparative Healthcare Cost between Robotic Esophagectomy and Video-Assisted Esophagectomy for Esophageal Cancer in Japan

    Dec 1, 2023, 00:00

  • HSD17 Key Features and Preferences for New High-Volume Low-Complexity Outpatient Care: Using Discrete Choice Experiments in Ophthalmology to Improve Diagnostic Service Delivery in England

    Dec 1, 2023, 00:00

  • RWD79 Impact of Google Searches on Suicide Rates in Colombia

    Dec 1, 2023, 00:00

  • EE577 Early Initiation of Guselkumab Increases Duration of Complete Remission (Psoriasis Area and Severity Index 100) in Patients With Moderate-to-Severe Psoriasis

    Dec 1, 2023, 00:00

  • EE496 Botulinum Toxin Type a for the Treatment of Focal Spasticity in Children with Cerebral Palsy in Thailand: A Cost-Utility Analysis

    Dec 1, 2023, 00:00

  • PCR140 Management of Osteogenesis Imperfecta: Self-Reported Access Challenges to Consumables and Services Across the EU5 and Nordics

    Dec 1, 2023, 00:00

  • EE295 Willingness to Pay for COVID-19 Vaccines in Hungary

    Dec 1, 2023, 00:00

  • CO61 Isatuximab in Multiple Myeloma: Safety and Effectiveness

    Dec 1, 2023, 00:00

  • EE320 Impact of NASH Disease Model Adjustment to New Literature Findings: Assessing Cost-Effectiveness of Actual and Theoretical Treatments

    Dec 1, 2023, 00:00

  • EPH109 Predictors of Individual General Life Satisfaction in the German General Social Survey (ALLBUS) Cohorts from 2010 to 2021

    Dec 1, 2023, 00:00

  • RWD32 Hearing the Patient Voice in Japan – Utilisation of Patient-Reported Outcomes and Wearable Device Data for Patient-Centric Real-World Research

    Dec 1, 2023, 00:00

  • EE137 Healthcare Resource Utilization and Estimated Costs in Adult Pneumococcal Disease in Peru: Results from a Panel of Experts

    Dec 1, 2023, 00:00

  • CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • RWD42 Stoma-Related Outcomes and Costs Associated with Initial Stoma Product Selection – Findings from a Swedish Register and Chart Review Study

    Dec 1, 2023, 00:00

  • EE524 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in Costa Rica

    Dec 1, 2023, 00:00

  • HTA132 Reporting Patient Preference Studies in Health Technology Assessment Submissions: Does It Make a Difference?

    Dec 1, 2023, 00:00

  • EE582 Actuarial Value Chain Modelling of Valoctocogene Roxaparvovec (VALROX) Therapy for Hemophilia A: An Adaptation from ICER Final Evidence Report*

    Dec 1, 2023, 00:00

  • PCR192 Content Validity of the EQ-5D and Health Utilities Index (HUI) to Assess Health-Related Quality-of-Life (HRQoL) Impact in Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2023, 00:00

  • PCR30 Benefits and Challenges of Different Qualitative Approaches in Rare Disease: A Case Study in Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Using a Narrative Exercise and Qualitative Interviews

    Dec 1, 2023, 00:00

  • MSR108 Geographic Search Filters for Embase.Com Interfa An Analysis Utilizing Multiple Case Studies

    Dec 1, 2023, 00:00

  • OP18 Are We Ready for a Digital Transformation in HEOR and Market Access?

    Dec 1, 2023, 00:00

  • HTA20 Predicting Post-AMNOG Price for a New Product Launch in Germany

    Dec 1, 2023, 00:00

  • EE348 The Economic Burden of Multiple Sclerosis in an Italian Cohort of Patients: Analysis of Disease Cost and Its Components

    Dec 1, 2023, 00:00

  • MSR44 Inflation, the Usual Suspect: Are Oncology Drugs Really Victims of the Macroeconomic Context?

    Dec 1, 2023, 00:00

  • PCR234 The Burden of Migraine in Czech Republic: Patient, Payer, and Societal Perspective

    Dec 1, 2023, 00:00

  • RWD37 Pre-/Post Prevalence of Cardiovascular Diseases in Hospitalized COVID Patients: A German Claims Data Analysis

    Dec 1, 2023, 00:00

  • HPR161 HTA and Economic Evaluations for a Genomic Strategy in Italy

    Dec 1, 2023, 00:00

  • A Longitudinal Evaluation of the Preferences of Patients With Advanced Cancer for Quality of Life and Survival in Malaysia: A Discrete Choice Experiment

    Dec 1, 2023, 00:00

  • EPH264 The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Adults Aged 60 and Older in Italy: Preliminary Results of a Markov Model Analysis

    Dec 1, 2023, 00:00

  • EE529 Methodology for the Monetization of Vial Remnants in the Aseptic Unit

    Dec 1, 2023, 00:00

  • EE657 Health Resource Utilization by Disease Stage for People with Amyotrophic Lateral Sclerosis (pALS) in the French National Health Data System (SNDS)

    Dec 1, 2023, 00:00

  • EPH236 Suicidal Behavior in Patients with Chronic Pain: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • MT65 Systematic Review of the Health-Economic Impact of Diagnostic Modality Selection for Patients with Coronary Artery Disease

    Dec 1, 2023, 00:00

  • SA66 Expert Elicitation Techniques: Informing Application in HTA Decision-Making

    Dec 1, 2023, 00:00

  • EE457 Cost-Effectiveness Analysis of Patiromer in Heart Failure Patients with Reduced Ejection Fraction for the Treatment of Hyperkalemia: Analysis of the Diamond Clinical Trial

    Dec 1, 2023, 00:00

  • EE517 Cost-Effectiveness Analysis of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Greece

    Dec 1, 2023, 00:00

  • EE533 Healthcare Resource Utilization (HCRU) and Related Direct Healthcare Costs for Patients with Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Cohort Study in a Clinical Practice Setting in Italy

    Dec 1, 2023, 00:00

  • HTA350 Fixed Effect Versus Random Effects Bayesian Network Meta-Analyses in Practi What Is Used to Inform National Institute for Health and Care Excellence (NICE) Technology Appraisals?

    Dec 1, 2023, 00:00

  • EE525 Cost Effectiveness of the Chimeric Antigen Receptor (CAR) T Cell Treatment Lisocabtagene Maraleucel (Liso-Cel) As Second-Line (2L) Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in Switzerland

    Dec 1, 2023, 00:00

  • PCR132 Correlation Between Quality of Life (QoL) of Patients Treated With Nivolumab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) and Their Caregivers

    Dec 1, 2023, 00:00

  • CO75 Non-Pharmacological Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Comprehensive Review

    Dec 1, 2023, 00:00

  • EPH91 The Incidence of Uveitis in the United Kingdom 2004-2021

    Dec 1, 2023, 00:00

  • HTA176 Feasibility of Cervical Cancer Screening Policy Using Self-Collected Samples for HPV DNA Testing in Thailand

    Dec 1, 2023, 00:00

  • P55 Prevalence and Predictors of Primary Non-Adherence to Medications Prescribed in Primary Care

    Dec 1, 2023, 00:00

  • HPR101 Maximizing the Quality of Comparative Evidence in Externally Controlled Studies—The Need for a Unified Framework

    Dec 1, 2023, 00:00

  • EE293 Estimation of the Cost of the National Immunization Program for Children and Adolescents in Greece

    Dec 1, 2023, 00:00

  • EPH171 Clinical, Economic, and Patient-Reported Impact of Obesity in the Asia-Pacific Region: A Systematic Review

    Dec 1, 2023, 00:00

  • PCR32 Patient Preference for Paroxysmal Nocturnal Haemoglobinuria Treatments: Analysis From the Q-Methodology of Treatment Attributes

    Dec 1, 2023, 00:00

  • HTA265 Development of the Reliant Checklist to Support the HTA Deliberation

    Dec 1, 2023, 00:00

  • EE719 Systematic Literature Review for Monetary Costs Data in Hemophilia

    Dec 1, 2023, 00:00

  • EE578 Estimating Economic Impact of Fenofibrate Among Patients with Diabetic Retinopathy in China

    Dec 1, 2023, 00:00

  • RWD64 A Nationwide Population-Based Study of Herbal Medicine for the Treatment of Functional Dyspepsia

    Dec 1, 2023, 00:00

  • CO49 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Ixekizumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis

    Dec 1, 2023, 00:00

  • HPR29 Evolution of the Utilization of the Aifa 5% Fund for Orphan Drugs and Rare Diseases

    Dec 1, 2023, 00:00

  • EE637 Economic Impact of Managing Invasive Mold Disease With Isavuconazole Compared With Liposomal Amphotericin B in Spain

    Dec 1, 2023, 00:00

  • HTA162 Canadian HTA and Early-Phase Evidence in Oncology: Current Trends and the Path Ahead

    Dec 1, 2023, 00:00

  • HPR93 Impact of Generic Competition on Prices, Public Spending and Utilization of Antiepileptic Medicines in Bulgaria

    Dec 1, 2023, 00:00

  • EE365 Discrepancies Between Actual Costs and Reimbursement Tariffs for Breast Cancer Radiotherapy in Indonesia: A Hospital-Based Retrospective Study

    Dec 1, 2023, 00:00

  • HSD46 Multidisciplinary Discussion for Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: A Cross Sectional Survey to Evaluate the Experiences of Multidisciplinary Teams in Italy

    Dec 1, 2023, 00:00

  • EPH13 RSV Hospitalizations’ Burden in New-Born Patients and Potential Impact of Maternal Vaccination: A French Analysis

    Dec 1, 2023, 00:00

  • HTA291 How Are Patients Involved in Health Technology Assessment? A Comparative Analysis of European Markets for Advanced Therapies and Implications for Joint Clinical Assessment

    Dec 1, 2023, 00:00

  • EE336 Cost-Effectiveness Analysis of Isavuconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Jordan

    Dec 1, 2023, 00:00

  • MSR137 Consideration of Competing Risks in Early Setting in Oncology and Impact on the Survival Estimates: To Explicitly Model Them? An Example of a French Real-World Cohort in Urothelial Carcinoma

    Dec 1, 2023, 00:00

  • EPH179 Ibuprofen, Other Nsaids, COVID-19: A Narrative Review

    Dec 1, 2023, 00:00

  • EE125 Cost Consequences of Using Clevidipine in Acute Hypertension from the Perspective of a US Hospital

    Dec 1, 2023, 00:00

  • MT45 Digital Health Applications in the General Practitioner Context of Care: An Empirical Analysis of Patient Acceptance

    Dec 1, 2023, 00:00

  • HTA228 Can Just Three PICOs be Feasible for Oncology Assessments with the Joint EU HTA Framework, Whilst Considering All 27 Member States Specificities?

    Dec 1, 2023, 00:00

  • EE591 Impact of Flu Vaccine Shortage on the National Health Service (NHS) in England and Wales

    Dec 1, 2023, 00:00

  • EPH255 Healthcare Resource Consumption of Patients with Cardiovascular Events after Exacerbations of Chronic Obstructive Pulmonary Disease in Italy: Results from the EXACOS-CV Study

    Dec 1, 2023, 00:00

  • PCR22 Solidifying Usability Testing Guidelines for Ecoas From the Patient Perspective

    Dec 1, 2023, 00:00

  • EE530 Global Clinical, Economic, Health-Related Quality of Life Burden, and Treatment Outcomes in Follicular Lymphoma: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA87 Mapping Accumulating Evidence Across Multiple Indications in Oncology Health Technology Assessment

    Dec 1, 2023, 00:00

  • EE749 Cost-Effectiveness Analysis of the Pediatric 20-Valent Pneumococcal Conjugate Vaccine Compared to Lower-Valent Alternatives in Argentina

    Dec 1, 2023, 00:00

  • RWD66 Characterization of the Variation of Opioid Prescription in 15 Dutch Hospitals: A Real World Data Analysis

    Dec 1, 2023, 00:00

  • EPH77 An Incidence- and Survival-Based Epidemiological Model for the Prevalence of Duchenne Muscular Dystrophy in Nine Countries

    Dec 1, 2023, 00:00

  • PCR227 Do Family Spillover Effects of Illness Vary With the Age of the Ill Individual?

    Dec 1, 2023, 00:00

  • RWD181 Improving Clinical Practice and Patient-Centric Care through Digital Outcome Measurement Tools

    Dec 1, 2023, 00:00

  • HTA121 The Triple Bottom Line in Healthcare: A Holistic Sustainability Assessment for Decision Support

    Dec 1, 2023, 00:00

  • PCR123 Assessing the Impact of Relapses on Burden to the Patient and Caregiver in NMOSD

    Dec 1, 2023, 00:00

  • MSR15 The Impact of Response Assessment Timing on Indirect Treatment Comparisons (ITCS) – A Simulation Study

    Dec 1, 2023, 00:00

  • HPR102 Factors Influencing Orphan Drug Net Prices in the EU4 and US – Insights from Payers

    Dec 1, 2023, 00:00

  • EE189 Combining Causal Inference and Within-Trial Economic Evaluation Methods to Assess the Cost-Effectiveness of a Mental Health Service Using Real-World Data: The Quasi-Experimental Adapt Study

    Dec 1, 2023, 00:00

  • HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?

    Dec 1, 2023, 00:00

  • EE162 Provider Budget Impact Model: Direct Transfer to Angiography Suite (DTAS) Without Stopping for CT Imaging for Patients With Acute Stroke in a German Setting

    Dec 1, 2023, 00:00

  • EE323 Cost Comparison Analysis of Patiromer Versus Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE278 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United Kingdom

    Dec 1, 2023, 00:00

  • EE95 Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece

    Dec 1, 2023, 00:00

  • MSR71 Projecting the Potential Impact of Disease Modifying Therapy on the Future Health and Social Costs of Alzheimer’s Disease

    Dec 1, 2023, 00:00

  • EE59 Real-Life Costs of Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated by CAR T-Cells in France Between 2017 and 2020 (EpiCART Study)

    Dec 1, 2023, 00:00

  • HSD19 Evaluation of Vascular Access Modality for Hemodialysis Patients: Analysis of Real-World Data in Italy

    Dec 1, 2023, 00:00

  • MSR109 Multi-Indication Evidence Synthesis in Oncology Health Technology Assessment: Case-Study on Bevacizumab

    Dec 1, 2023, 00:00

  • EE619 A Cost-Utility Analysis of Low-Dose vs Standard-Dose Intravenous Alteplase in the Management of Acute Non-Lacunar Ischaemic Strokes: A Perspective From the NHS

    Dec 1, 2023, 00:00

  • HTA212 Level of ICER of Health Economic Assessment in France in 2022

    Dec 1, 2023, 00:00

  • RWD106 The Maze of RWE Frameworks: An Environmental Scanning and Comparison Across Regulatory and HTA Bodies

    Dec 1, 2023, 00:00

  • EPH269 Estimating the Burden of Vaccine-Preventable Infectious Diseases Caused by Herpesviruses Beyond Herpes Zoster in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • HTA156 Health Technology Assessment of Multiple Myeloma Therapies: Value Demonstration and Value Recognition Challenges

    Dec 1, 2023, 00:00

  • CO169 Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies in the Framework of the EU Project, Harmony: the Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology

    Dec 1, 2023, 00:00

  • PCR251 Economic and Humanistic Burden of Visual Impairment and Blindness in Patiens and Their Caregivers with Retinitis Pigmentosa or Leber Congenital Amaurosis (E-BIRDS Study)

    Dec 1, 2023, 00:00

  • HTA116 Cost-Effectiveness of Nirmatrelvir/Ritonavir for the Treatment of Outpatient Sars-Cov-2 in Adult Patients at Risk for Developing Severe Disease in Greece

    Dec 1, 2023, 00:00

  • EE640 The Impact of Blue-Light Emitting Device on the Loss of Productivity From COVID-19 in North Carolina

    Dec 1, 2023, 00:00

  • RWD164 The Impact of Spinal Muscular Atrophy (SMA) Type 1 on Caregivers in Taiwan: Results of a Global Survey

    Dec 1, 2023, 00:00

  • HTA50 Assessing the Risk of Bias in Clinical Trials for Health Technology Assessments: Should Existing Tools Reflect the ICH E9(R1) Addendum on Estimands and Sensitivity Analyses?

    Dec 1, 2023, 00:00

  • PCR19 The EU Patient Community's Perspectives on Data Protection and Data Control

    Dec 1, 2023, 00:00

  • RWD68 How Pharmaceutical, Biotechnology and Medical Technology Companies Use Clinical Practice Research Datalink (CPRD) Data: Rapid Structured Review Using Machine Learning

    Dec 1, 2023, 00:00

  • PCR256 Correlation of Patient-Reported Vitiligo Noticeability Scale With Physician-Assessed Facial Vitiligo Area Scoring Index Responses: Post Hoc Analyses From the True-V Trials of Ruxolitinib Cream in Vitiligo

    Dec 1, 2023, 00:00

  • EPH135 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Egypt

    Dec 1, 2023, 00:00

  • HTA154 Trends of Indirect Treatment Comparison Methods Use in NICE Technology Appraisals for Haematologic Cancers

    Dec 1, 2023, 00:00

  • HTA25 What Is a Highly Specialised Technology (HST)? The Revised NICE HST Criteria in Practice

    Dec 1, 2023, 00:00

  • MT31 The Promising Future of Digital Health: A Road to Reimbursement in US EU5 Markets?

    Dec 1, 2023, 00:00

  • RWD138 Rising Adoption of Healthcare Wearables in Clinical Study Design

    Dec 1, 2023, 00:00

  • EE5 The Health Return on Investment (ROI) Assessor: Evaluating Novel Cardiovascular Disease (CVD) Prevention Approaches in Estonia

    Dec 1, 2023, 00:00

  • EE471 Investigating the Impact of Pseudo-Random Numbers Generator on a Probabilistic Sensitive Analysis (PSA) Results

    Dec 1, 2023, 00:00

  • HPR130 Analysis of Extemporaneous Compounding of Medicines During COVID-19 and Wartime in Ukraine

    Dec 1, 2023, 00:00

  • EPH108 Quality of Life of Menopausal Women

    Dec 1, 2023, 00:00

  • SA11 A Systematic Review on the Safety and Effectiveness of the Active Middle Ear Implant in the Treatment of Conductive and Mixed Hearing Loss

    Dec 1, 2023, 00:00

  • PT42 The Impact of Spinal Muscular Atrophy Type 2 on Caregivers in Argentina: Results of a Global Survey

    Dec 1, 2023, 00:00

  • PCR265 A Core Outcome Set for the Evaluation of New Healthcare Programs in Sweden

    Dec 1, 2023, 00:00

  • RWD51 Application of Real-World Data Sources for Equity-Informed Evaluations of Multiple Myeloma

    Dec 1, 2023, 00:00

  • Epidemiology Public Health

    Dec 1, 2023, 00:00

  • RWD99 Characterization of Comorbidities and Economic Burden in US Medicare Beneficiaries with Systemic Lupus Erythematosus with and without Lupus Nephritis

    Dec 1, 2023, 00:00

  • HTA303 Are BSC and Patient-Individual Therapy as Appropriate Comparators Detrimental for AMNOG Benefit Assessment and Price Rebates in Germany?

    Dec 1, 2023, 00:00

  • HTA219 Examining the Awareness and Perceptions of EU HTA Amongst Irish Pharmaceutical Industry Professionals

    Dec 1, 2023, 00:00

  • HTA343 Machine Learning Prediction of Drug Overdoses Among Young People

    Dec 1, 2023, 00:00

  • HSD107 Descriptive Analysis of Changes to Cardiovascular Healthcare Resource Use Recorded in Malaysian Real World Data from the Syntium Database before, during and after the COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • P51 Testing a Survival Extrapolation Algorithm for Cancer Immunotherapies: Pass or Fail?

    Dec 1, 2023, 00:00

  • HTA128 Use of Patient Preference Studies in NICE Submissions in the Last 5 Years

    Dec 1, 2023, 00:00

  • HSD40 Fecal Incontinence of Patients After Stoma Reversal: A German Claims Data Analysis Reveals Concerns

    Dec 1, 2023, 00:00

  • EE650 Incremental Costs of Tofacitinib Compared to Adalimumab and Ixekizumab for the Treatment of Active Ankylosing Spondylitis in Denmark

    Dec 1, 2023, 00:00

  • HTA183 Setting the Right Discount Rate for Health Technology Assessment in the Slovak Republic

    Dec 1, 2023, 00:00

  • EPH126 Gender-Affirming Hormone Therapy and Psychological Distress Among Transgender and Nonbinary People: Differences by Source of Hormones

    Dec 1, 2023, 00:00

  • CO19 Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Dec 1, 2023, 00:00

  • CO188 Mortality and Clinical Complications Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France

    Dec 1, 2023, 00:00

  • EE716 Resource Utilisation and Healthcare Costs Among Patients with Age-Related Macular Degeneration (NAMD) in Italy: Findings from the Radiance Observational Substudy

    Dec 1, 2023, 00:00

  • PT14 Bayesian Meta-Analysis of Data From Trials of Mixed Patient Populations to Inform Health Economic Models for Patients Harboring a Predictive Biomarker

    Dec 1, 2023, 00:00

  • SA81 Has the Publication of China Guidelines for Pharmacoeconomic Evaluations 2020 influenced the Study Quality of Economic Evaluations in China? A Systematic Review

    Dec 1, 2023, 00:00

  • EPH33 Postpartum Hemorrhage: A Look into Colombia's Health System

    Dec 1, 2023, 00:00

  • PCR175 Real-World Impact of Migraine on Canadians’ Productivity: A Pharmacy-Based Study

    Dec 1, 2023, 00:00

  • EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada

    Dec 1, 2023, 00:00

  • EPH5 Prevalence and Predictive Factors of Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography

    Dec 1, 2023, 00:00

  • MSR87 How Many Simulations of a Dynamic Transmission Model Are Enough to Estimate Uncertainty?

    Dec 1, 2023, 00:00

  • PCR205 Determination of Ranges of HSSDD HSSQ Scores Defining Clinically Meaningful Within-Patient Improvement Thresholds and Severity Levels

    Dec 1, 2023, 00:00

  • PT43 Cost-Effectiveness Analysis of Prostate-Specific Antigen (PSA)-Based Risk-Adapted Screening in Germany: An Early Economic Evaluation Study

    Dec 1, 2023, 00:00

  • HTA109 A Review of the Use of Indirect Treatment Comparisons to Support Health Technology Assessments in Ireland

    Dec 1, 2023, 00:00

  • Patient-Centered Research

    Dec 1, 2023, 00:00

  • EPH139 A Retrospective Cohort Study of Pediatric Patients Undergoing Percutaneous Vascular Procedures

    Dec 1, 2023, 00:00

  • HTA5 An Evaluation of the NICE Early Value Assessment: What Is the Opportunity for Digital Therapeutics?

    Dec 1, 2023, 00:00

  • HTA269 Are We Leaving No One behind? Health Technology Assessment as a Pathway to Social Justice

    Dec 1, 2023, 00:00

  • PCR17 The Development of a Comprehensive Archive of Patient-Reported Outcome Measures (PROMS) for Clinical Research and Clinical Practice in Oncology

    Dec 1, 2023, 00:00

  • HTA155 The Impact of Phase 2 Clinical Trials on Reimbursement Recommendations in Oncology By Canadian Health Technology Assessment Agencies

    Dec 1, 2023, 00:00

  • HSD81 Automated Report Generation with Chat GPT API for Cardiology: Performance Evaluation and Impact on Physician Burnout

    Dec 1, 2023, 00:00

  • MSR144 The Impact of Enhanced Access to Modern Antineoplastic Drugs for Breast Cancer Treatment on Mortality and Economic Development

    Dec 1, 2023, 00:00

  • HTA264 Baseline Natural History Models in Network Meta-Analysis: Guidance Versus Implementation in National Health and Care Excellence (NICE) Appraisals

    Dec 1, 2023, 00:00

  • CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?

    Dec 1, 2023, 00:00

  • EE435 Cost-Analysis of a Machine Learning-Based Clinical Decision Support System to Guide Resilience-Strengthening Intervention Decisions in Breast Cancer Treatment: The Bounce Study

    Dec 1, 2023, 00:00

  • PCR57 A Qualitative Interview Study to Evaluate Single-Tablet Combination Therapy (STCT) Within a Phase 3 Pulmonary Arterial Hypertension (PAH) Clinical Trial – Interim Analysis

    Dec 1, 2023, 00:00

  • PCR3 EQ-5D Utilities for Patients With Nonalcoholic Steatohepatitis (NASH): A Comparison of Historical Utilities to a Recent Real-World Multi-Country Patient Survey

    Dec 1, 2023, 00:00

  • MSR143 Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    Dec 1, 2023, 00:00

  • P10 Impact of the COVID-19 Pandemic on Cancer Screenings in Portugal and Years of Life Lost Due to Delayed Diagnoses

    Dec 1, 2023, 00:00

  • HTA89 An Increased Use of External Data to Inform Survival Extrapolations in NICE Technology Appraisals

    Dec 1, 2023, 00:00

  • CO58 Patient Characteristics and Treatment Patterns in Patients with Mantle Cell Lymphoma in Spain: A Real-World, Cross-Sectional Study

    Dec 1, 2023, 00:00

  • EE164 Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol

    Dec 1, 2023, 00:00

  • RWD19 Risk of Death Before and After Metastasis in High-Risk Localized and Locally Advanced Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy as Primary Treatment in the United States: A Retrospective Study

    Dec 1, 2023, 00:00

  • HTA144 NICE Value Male Lives More Than Female Lives?

    Dec 1, 2023, 00:00

  • HTA272 EUnetHTA's HTA Core Model®: A Critical Assessment and Future Outlook

    Dec 1, 2023, 00:00

  • OP5 Multistakeholder Healthcare Cooperative: A New Paradigm for Healthcare Delivery

    Dec 1, 2023, 00:00

  • RWD28 Healthcare Resource Utilization and Cost of Renal Replacement Therapy in Brazil: A Five-Year Patient-Level Analysis

    Dec 1, 2023, 00:00

  • HTA78 Examining the Influence of Study Design, Incremental Medical Benefit, and Price-Setting Pathway on Pricing of Digital Health Applications in Germany

    Dec 1, 2023, 00:00

  • P34 Health Technology Assessments of Digital Public Health Interventions in the Southeast Asia - A Systematic Scoping Review

    Dec 1, 2023, 00:00

  • PT24 Reimbursement Decisions in Ireland; Utilising Text Mining to Assess Factors Contributing to Decision Making

    Dec 1, 2023, 00:00

  • EE332 Evaluation of Hospital Pandemic Control Strategies of a Chinese Tertiary Care Hospital During the Late Phase of COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • HTA231 What Is the Psycho-Oncologic (PsyO) Impact of Progression in Patients with Cancer? A Targeted Literature Review (TLR) to Assess the Available Data

    Dec 1, 2023, 00:00

  • SA52 Clinical Impact of Using Digital Healthcare Technology to Manage Diabetes in Adolescents.: A Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • PCR27 Association between Health-Related Quality of Life and Requirement for Non-Professional Care in Adults with Rare Diseases: A Real-World Study

    Dec 1, 2023, 00:00

  • EE12 An Economic Model Comparing Fever Management to Fever Prevention With Advanced Targeted Temperature Management (ATTM) in Out-of-Hospital Cardiac Arrest (OHCA) Patients

    Dec 1, 2023, 00:00

  • RWD63 Clinical Outcomes in Non-Inhibitor Severe Haemophilia A Patients Receiving Prophylaxis Across Currently Available Haemophilia A Treatments: Insights Form the ‘Cost of Haemophilia: A Socioeconomic Survey III’ (CHESS III) Study

    Dec 1, 2023, 00:00

  • PCR266 Transplant Physicians’ Preferences in Deceased Organ Allocation: A Pilot Discrete Choice Experiment

    Dec 1, 2023, 00:00

  • EPH38 Exploring the Relationship Between Hemochromatosis and Fracture Risk: A Population-Based Matched Cohort Study Stratified on Ferritin Levels

    Dec 1, 2023, 00:00

  • CO160 Burden of Illness and Treatment Patterns of Adult Patients with Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • SA82 Systematic Versus Rapid Review: The Impact of Database Coverage and Single Studies Selection on the Review's Conclusions

    Dec 1, 2023, 00:00

  • HPR18 How Will Recent Pricing Regulations Impact the Global Pricing Landscape?

    Dec 1, 2023, 00:00

  • EE468 The Full Circle: Systematic Evaluation, Replication and Validation of Structural Health Economic Modelling Approaches: Lessons Learned in the Field of Obesity

    Dec 1, 2023, 00:00

  • EE515 Economical Impact of Dose Reduction Treatment for Ribociclib, Palbociclib and Abemaciclib in Colombia

    Dec 1, 2023, 00:00

  • PCR238 Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Quality Appraisal of Patient-Reported Outcome (PRO) Instruments

    Dec 1, 2023, 00:00

  • EPH96 Projected Prevalence of Acute, Chronic, and End-Stage Kidney Disease in the UK From 2023 to 2033

    Dec 1, 2023, 00:00

  • MSR41 Machine Learning and Patient-Reported Outcomes (PROs) in Oncology: A Systematic Literature Review on Methodological Quality

    Dec 1, 2023, 00:00

  • EPH134 Prevalence of and Associated Factors for Therapy Delay Due to COVID-19 Pandemic Among Breast Cancer Patients in Europe

    Dec 1, 2023, 00:00

  • PCR120 A Psychometric Evaluation of the RAND 36 Scale Among Japanese Adults With Insomnia in 2023

    Dec 1, 2023, 00:00

  • CO63 Systematic Literature Review of Health-Related Quality of Life in Advanced or Metastatic Esophageal Cancer

    Dec 1, 2023, 00:00

  • HTA204 A Retrospective of the HAS Economic Appraisals Over the Last Ten Years

    Dec 1, 2023, 00:00

  • EE400 Cost-Effectiveness of Cannabidiol (CBD) for the Treatment of Seizures in Patients with Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands

    Dec 1, 2023, 00:00

  • HTA216 Analyzing Delays in Economic Appraisal in France : A Comparative Study of 2021 and 2022

    Dec 1, 2023, 00:00

  • EE585 Threshold Price Analysis of Micro-Hole Zone Technology Catheters Compared to Standard Hydrophilic-Coated Catheters in Long-Term Intermittent Catheter Users in the UK

    Dec 1, 2023, 00:00

  • EPH131 Landscape Analysis of Alzheimer's Disease-Specific Caregiver Outcome Assessments

    Dec 1, 2023, 00:00

  • CO106 A Structured Expert Elicitation Exercise Conducted With UK Clinicians to Inform and Validate Inputs for a Cost-Effectiveness Analysis of FILSUVEZ® Gel (Birch Bark Extract) in Epidermolysis Bullosa

    Dec 1, 2023, 00:00

  • Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report

    Dec 1, 2023, 00:00

  • MSR69 Modelling Social and Economic Burden of Hepatits C in Russia in Different Scenarios of Control Measures up to 2035

    Dec 1, 2023, 00:00

  • HTA349 Impact of Technical Exchanges on CEESP Reservations: Analysis of the 2022 CEESP Opinions

    Dec 1, 2023, 00:00

  • EPH231 The Impact of COVID-19 on National Disease Dynamics: Population-Based Interrupted Time Series Study in South Korea

    Dec 1, 2023, 00:00

  • CO34 Mortality and Clinical Complications Among Patients with Transfusion-Dependent Beta-Thalassemia in France

    Dec 1, 2023, 00:00

  • HTA80 To What Extent Do the EUnetHTA 21 D4.4 Guidelines on Endpoints Recognize Non-Os Endpoints and Patient-Reported Outcomes, and What Opportunities Exist in the Joint Clinical Assessment to Reflect Their Value?

    Dec 1, 2023, 00:00

  • EE586 Comparison of Enteral Nutritional Therapy to Induce and Maintain Remission in Paediatric Patients with Mild-to-Moderate Crohn’S Disease: A Cost-Effectiveness Analysis in the UK

    Dec 1, 2023, 00:00

  • EE599 Selection of Post-Patient Death Caregiver and Family Utilities When Estimating Spillover Effects

    Dec 1, 2023, 00:00

  • EE557 Economic Burden of Cystic Fibrosis in Five Key European Countries: A Systematic Review

    Dec 1, 2023, 00:00

  • EE401 A Comparison of Health State Occupancy Between Cipaglucosidase Alfa/Miglustat and Alglucosidase Alfa Within a Cost-Effectiveness Modelling Analysis of Late-Onset Pompe Disease

    Dec 1, 2023, 00:00

  • PT11 Overall Survival of Patients with Lung Cancer Newly Diagnosed in the Period of the COVID-19 Pandemic Compared to Patients with an Incident Diagnosis Before the Pandemic: A Retrospective Analysis of German Claims Data

    Dec 1, 2023, 00:00

  • HPR117 Underinvestment in Poland and Its Impact on Health Outcomes

    Dec 1, 2023, 00:00

  • EE44 Health Care Resource Utilization and Cost in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada

    Dec 1, 2023, 00:00

  • PCR75 Real-World Evidence of Outcomes of Fulvestrant Monotherapy After Progression on CDK4/6 Inhibitor + Aromatase Inhibitor in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Dec 1, 2023, 00:00

  • P8 The Dutch Lock Procedure for Reimbursement Works as Intended

    Dec 1, 2023, 00:00

  • PCR163 Modification of the Social Ecological Model to Distinguish the Terms “HRQoL” and “QoL” in Patient-Centered Outcomes Research

    Dec 1, 2023, 00:00

  • MSR138 On When and How to Use External Data to Inform Long-Term Survival Curve Extrapolation

    Dec 1, 2023, 00:00

  • HTA37 Assessing the Definition and Outcomes of Innovative Drugs by Health Technology Assessment Bodies in England, France, and Italy (Q1 2023)

    Dec 1, 2023, 00:00

  • EE713 Cost-of-Illness of Generalized Pustular Psoriasis in Italy

    Dec 1, 2023, 00:00

  • HTA232 A Multi-Criteria Decision Analysis Framework for the Value Assessment of First-Line Treatment of Adult Patients with Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • PCR186 Patient Engagement in Real-World Data Collection: User Characteristics of a Health App for People Living With Pancreatic Cancer

    Dec 1, 2023, 00:00

  • MT44 Submission Process and Requirements of Nordic Health Technology Assessment Organisations for Medical Technologies: Results of an Online Survey

    Dec 1, 2023, 00:00

  • EE109 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in France

    Dec 1, 2023, 00:00

  • EE42 Comparison of Cost of Incident Rheumatoid Arthritis Patients in Turkey with Selected European Countries

    Dec 1, 2023, 00:00

  • CO35 Clinical Outcomes Associated with Sodium Zirconium Cyclosilicate for Treating Hyperkalaemia in Patients Receiving Haemodialysis

    Dec 1, 2023, 00:00

  • CO130 Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend

    Dec 1, 2023, 00:00

  • EPH257 Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data

    Dec 1, 2023, 00:00

  • HSD58 Real-World Prescribing of Long-Acting Injectable Cabotegravir for Treatment of HIV in the United States

    Dec 1, 2023, 00:00

  • HTA206 How Do the Stricter Pricing Regulations of the Statutory Health Insurance Financial Stabilization Act (GKV-FINSTG) Affect Reimbursement Prices of New Drugs in Germany?

    Dec 1, 2023, 00:00

  • HPR80 Examination of the Changes in the Turkish Pharmaceutical Market between 2007 and 2021

    Dec 1, 2023, 00:00

  • EE745 Cost- Effectiveness of Pneumococcal Vaccination for Adults Aged 60 Years and Older in Peru

    Dec 1, 2023, 00:00

  • CO139 Acalabrutinib (AKA) Versus Venetoclax With Obinutuzumab (VEN+OBI) in Patients With Untreated Chronic Lymphocytic Leukemia (CLL) and Unmutated IGHV Genes – Indirect Comparison

    Dec 1, 2023, 00:00

  • SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy

    Dec 1, 2023, 00:00

  • EE753 Cost-Effectiveness Analysis of Fracture Prevention with 25-Hydroxyvitamin D (25(OH)D) Screening Among the Population over 65 Years Old in China

    Dec 1, 2023, 00:00

  • HPR109 What Drives Socially Acceptable Costs in Outcomes Based Agreements? a Survey Studying Gene Therapies

    Dec 1, 2023, 00:00

  • HTA33 Are Digital Health Therapeutics Reshaping the HTA Framework for Health Technologies?

    Dec 1, 2023, 00:00

  • HTA36 Monitoring of the Long-Term Impact of the COVID-19 Pandemic on the Decision Process of the Italian Medicine Agency

    Dec 1, 2023, 00:00

  • PT2 Comparing UK Value Sets and Mapping Functions for EQ-5D

    Dec 1, 2023, 00:00

  • EPH229 Hospitalization Patterns and Costs of Primary Biliary Cholangitis (PBC) in Germany

    Dec 1, 2023, 00:00

  • EE501 Impact of Eptinezumab on Healthcare Resource Utilization in Patients with Migraine in the United States: A Retrospective Cohort Claims Database Study

    Dec 1, 2023, 00:00

  • EE482 Economic Cost of Implementation of a Frailty Care Bundle to Reduce Risk of Hospital Associated Decline Among Older Patients

    Dec 1, 2023, 00:00

  • CO109 A Targeted Review of Pharmacological Therapies for the Treatment of Chronic Spontaneous Urticaria

    Dec 1, 2023, 00:00

  • EE257 Real-World, Longitudinal, Retrospective Study of Healthcare Resource Utilization of Patients With Atopic Dermatitis Under the Public Health Insurance Plan of Quebec, Canada

    Dec 1, 2023, 00:00

  • HTA271 Shifting Landscape of Indirect Comparison Methodologies and Their Role in Informing NICE Decision-Making Processes

    Dec 1, 2023, 00:00

  • EE214 The Cost-Effectiveness of Abemaciclib Combined With Endocrine Therapy (ET) for the Treatment of Persons With HR+, HER2- Node Positive, Early Breast Cancer (EBC) at High Risk of Recurren A Spanish Healthcare Perspective

    Dec 1, 2023, 00:00

  • SA71 Real-World Treatment Patterns for Acute Lymphoblastic Leukemia Utilizing Claims Data

    Dec 1, 2023, 00:00

  • PCR53 To What Extent European Value-Based Pricing Methodologies Take Into Account Patient Perspectives and Broader Societal Benefits?

    Dec 1, 2023, 00:00

  • EE228 Cost to Society and Financial Toxicity Related to Personalized Oncology Treatment in Bulgaria

    Dec 1, 2023, 00:00

  • MSR13 Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC)

    Dec 1, 2023, 00:00

  • MSR118 Identifying Potential Long-COVID Patients Using Machine Learning: A German Claims Data Analysis

    Dec 1, 2023, 00:00

  • EE698 A Systematic Literature Review of Economic Evaluations in Primary Biliary Cholangitis

    Dec 1, 2023, 00:00

  • PT12 Perceived Financial Burden and Quality of Life Among Patients with Cancer

    Dec 1, 2023, 00:00

  • PCR43 A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)

    Dec 1, 2023, 00:00

  • EE635 Medical Cost Trends for Diseases Associated with Bedridden Rural Residents in Japan

    Dec 1, 2023, 00:00

  • EPH102 Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) Among Canadian Infants

    Dec 1, 2023, 00:00

  • EPH117 The Phollow Cohort: Real-World Therapeutic Adherence to Blood Glucose-Lowering Drugs (EXCLUDING INSULINS) in Portugal

    Dec 1, 2023, 00:00

  • EE647 Excess Healthcare Resource Use Among Subgroups With Anxiety and Depressive Symptoms in Hungary

    Dec 1, 2023, 00:00

  • PCR88 Use of Patient-Reported Outcomes for Sickle-Cell Disease in Clinical Trials – Do They Match with Consensus-Based Core Outcomes Sets Recommendations?

    Dec 1, 2023, 00:00

  • RWD148 Using Linked Data: Agreement in Diagnosis for Patients with Asthma or Diabetes

    Dec 1, 2023, 00:00

  • RWD127 Systemic Treatment of Non-Melanoma Skin Cancers in Fran Real-World Analysis Using French Data from the National Hospitalization Database

    Dec 1, 2023, 00:00

  • EE50 What Is the Economic Impact of an Early Adoption of High Efficacy Treatments in Multiple Sclerosis? A Cost-Consequence Analysis From a Societal Perspective in the Portuguese Setting

    Dec 1, 2023, 00:00

  • EPH197 An Integrated Modelling Methodology for Estimating Global, Regional, and Country-Specific Incidence and Prevalence of Tay-Sachs Disease at the Subtype Level

    Dec 1, 2023, 00:00

  • EE554 Cost-Effectiveness Analysis of Novoseven® Treatment for Postpartum Hemorrhage in Turkiye

    Dec 1, 2023, 00:00

  • MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain

    Dec 1, 2023, 00:00

  • PT46 Does Public Research Investment on Emerging Infectious Diseases Correspond to Disease Burden in China? A Cross-Sectional Study from 2009 to 2019

    Dec 1, 2023, 00:00

  • PCR104 Is It Worth the Risk? Challenges and Recommendations for Devising Attributes and Levels for Safety-Related Attributes in Patient Preference Studies

    Dec 1, 2023, 00:00

  • MSR91 What Are Unmet Needs for the Use of Registries in Regulatory/HTA Decision-Making in Europe? A Survey-Based Approach From the More-EUROPA Project

    Dec 1, 2023, 00:00

  • EE358 A Systematic Literature Review of Reviews Related to the Impacts of Catastrophic Health Expenditures Related to Cancer Care

    Dec 1, 2023, 00:00

  • EPH39 Epidemiology and Patient Characteristics of Pemphigus Vulgaris in Italy Based on Administrative Database

    Dec 1, 2023, 00:00

  • EE161 Economic Burden Associated with Stroke: A Comparative Analysis of Post-Stroke Care Costs

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22
  • 23
  • 24 (current)
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »